Clinical experience with Hedgehog pathway inhibitors.

Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01

The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer (2011) 2.60

Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell (2014) 2.57

Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol (2011) 2.53

Hedgehog signaling controls T cell killing at the immunological synapse. Science (2013) 1.84

Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol (2012) 1.50

Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One (2011) 1.29

The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.26

Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol (2012) 1.24

Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res (2013) 1.20

Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol (2011) 1.18

The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. Oncotarget (2011) 1.17

The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.14

Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res (2013) 1.08

Molecular subgroups of medulloblastoma. Expert Rev Neurother (2012) 1.05

The hedgehog processing pathway is required for NSCLC growth and survival. Oncogene (2012) 1.05

The hedgehog receptor patched is involved in cholesterol transport. PLoS One (2011) 1.00

PCAF ubiquitin ligase activity inhibits Hedgehog/Gli1 signaling in p53-dependent response to genotoxic stress. Cell Death Differ (2013) 1.00

FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer. Cell Rep (2015) 0.98

Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. World J Gastroenterol (2014) 0.97

Regulation of DNA damage following termination of Hedgehog (HH) survival signaling at the level of the GLI genes in human colon cancer. Oncotarget (2012) 0.97

Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding. Oncotarget (2014) 0.94

The molecular classification of medulloblastoma: driving the next generation clinical trials. Curr Opin Pediatr (2012) 0.94

The utility of hedgehog signaling pathway inhibition for cancer. Oncologist (2012) 0.94

Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway. PLoS One (2013) 0.94

Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Mol Cancer Res (2011) 0.94

Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo. J Biol Chem (2012) 0.93

Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol (2011) 0.92

Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthal Plast Reconstr Surg (2013) 0.90

Stem cell biology and drug discovery. BMC Biol (2011) 0.90

Gli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors. J Biol Chem (2014) 0.89

Cetuximab in refractory skin cancer treatment. J Cancer (2012) 0.88

Targeting Gli transcription activation by small molecule suppresses tumor growth. Oncogene (2013) 0.88

Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86

Hedgehog signaling pathway is active in GBM with GLI1 mRNA expression showing a single continuous distribution rather than discrete high/low clusters. PLoS One (2015) 0.85

PBOV1 is a human de novo gene with tumor-specific expression that is associated with a positive clinical outcome of cancer. PLoS One (2013) 0.84

Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Autophagy (2015) 0.83

Targeting developmental pathways in children with cancer: what price success? Lancet Oncol (2013) 0.82

Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression. Mol Cancer Res (2013) 0.81

Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. Int J Oncol (2012) 0.80

Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome. Stem Cells Int (2015) 0.80

Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling. Bioorg Med Chem (2012) 0.79

Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Mol Cancer Ther (2014) 0.78

Extrinsic aging: UV-mediated skin carcinogenesis. Dermatoendocrinol (2012) 0.78

A novel synthetic smoothened antagonist transiently inhibits pancreatic adenocarcinoma xenografts in a mouse model. PLoS One (2011) 0.78

The Hedgehog pathway effector smoothened exhibits signaling competency in the absence of ciliary accumulation. Chem Biol (2014) 0.77

Investigational Notch and Hedgehog inhibitors--therapies for cardiovascular disease. Expert Opin Investig Drugs (2011) 0.77

Hedgehog Cholesterolysis: Specialized Gatekeeper to Oncogenic Signaling. Cancers (Basel) (2015) 0.77

Advances in paediatric cancer treatment. Transl Pediatr (2014) 0.76

All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched. Cancer Biol Ther (2014) 0.76

Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers. Br J Clin Pharmacol (2016) 0.76

p53 modulates the activity of the GLI1 oncogene through interactions with the shared coactivator TAF9. DNA Repair (Amst) (2015) 0.76

Present status and upcoming prospects of hedgehog pathway inhibitors in small cell lung cancer therapy. Infect Agent Cancer (2013) 0.76

Targeted therapy for advanced Basal-cell carcinoma: vismodegib and beyond. Dermatol Ther (Heidelb) (2013) 0.76

Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma. Onco Targets Ther (2016) 0.76

Origins of the cytolytic synapse. Nat Rev Immunol (2016) 0.75

Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas. Onco Targets Ther (2017) 0.75

Epigenetic deregulation of Ellis Van Creveld confers robust Hedgehog signaling in adult T-cell leukemia. Cancer Sci (2014) 0.75

Hepatocellular Carcinoma: Basic and Transitional Research. Gastrointest Tumors (2014) 0.75

Unraveling the therapeutic potential of the LncRNA-dependent noncanonical Hedgehog pathway in cancer. Mol Cell Oncol (2015) 0.75

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. Onco Targets Ther (2016) 0.75

Development of thieno- and benzopyrimidinone inhibitors of the Hedgehog signaling pathway reveals PDE4-dependent and PDE4-independent mechanisms of action. Bioorg Med Chem Lett (2016) 0.75

Control of inflammation by stromal Hedgehog pathway activation restrains colitis. Proc Natl Acad Sci U S A (2016) 0.75

Expression of microRNAs in tumors of the central nervous system in pediatric patients in México. Childs Nerv Syst (2017) 0.75

The Hedgehog-GLI pathway in embryonic development and cancer: implications for pulmonary oncology therapy. Oncotarget (2017) 0.75

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem (2002) 14.34

Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med (2008) 12.68

Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83

The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55

A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23

Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol (2006) 6.82

A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature (2011) 5.45

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40

Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov (2006) 5.30

Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10

Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47

Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci (2009) 3.74

Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A (2009) 3.13

A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol (2010) 3.09

The mammalian Cos2 homolog Kif7 plays an essential role in modulating Hh signal transduction during development. Curr Biol (2009) 2.63

Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res (2010) 2.45

Paracrine Hedgehog signaling in cancer. Cancer Res (2009) 2.21

The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res (2012) 2.19

The hedgehog signaling pathway in cancer. Clin Cancer Res (2006) 2.15

Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06

Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J Immunol (2008) 1.92

IL-27 limits IL-2 production during Th1 differentiation. J Immunol (2006) 1.89

Kinetics of hedgehog-dependent full-length Gli3 accumulation in primary cilia and subsequent degradation. Mol Cell Biol (2010) 1.81

TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal (2011) 1.81

Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res (2011) 1.72

Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Res (2005) 1.69

Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell (2009) 1.61

Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology. Am J Pathol (2006) 1.57

Hedgehog signaling regulates the generation of ameloblast progenitors in the continuously growing mouse incisor. Development (2010) 1.55

Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol (2005) 1.54

Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J Immunol (2005) 1.48

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res (2012) 1.47

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res (2009) 1.41

IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J Exp Med (2010) 1.41

Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood (2008) 1.39

Loss of the serine/threonine kinase fused results in postnatal growth defects and lethality due to progressive hydrocephalus. Mol Cell Biol (2005) 1.39

Suppressor of fused regulates Gli activity through a dual binding mechanism. Mol Cell Biol (2004) 1.38

IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med (2007) 1.34

Kinome siRNA screen identifies regulators of ciliogenesis and hedgehog signal transduction. Sci Signal (2008) 1.33

Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cells. Proc Natl Acad Sci U S A (2011) 1.23

Structural ties between cholesterol transport and morphogen signaling. Cell (2009) 1.18

A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5. J Biol Chem (2002) 1.17

miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal (2011) 1.16

The structure of SHH in complex with HHIP reveals a recognition role for the Shh pseudo active site in signaling. Nat Struct Mol Biol (2009) 1.15

Dissecting the oncogenic potential of Gli2: deletion of an NH(2)-terminal fragment alters skin tumor phenotype. Cancer Res (2002) 1.15

Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site. J Biol Chem (2010) 1.13

Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation. Clin Cancer Res (2011) 1.10

Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res (2011) 1.02

PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition. Cancer Res (2013) 1.00

Prostate-specific Klf6 inactivation impairs anterior prostate branching morphogenesis through increased activation of the Shh pathway. J Biol Chem (2009) 0.96

Discovery and preclinical development of vismodegib. Expert Opin Drug Discov (2014) 0.95

TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma. PLoS One (2011) 0.93

Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway. Bioorg Med Chem Lett (2010) 0.91

A tumor-specific stem cell. Nat Genet (2013) 0.85

Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31. Exp Hematol (2007) 0.84

Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Pancreatology (2011) 0.82

Signaling: An oxysterol ligand for Smoothened. Nat Chem Biol (2012) 0.81

Structure of SAP18: a ubiquitin fold in histone deacetylase complex assembly. Biochemistry (2006) 0.80

Vive la science! Vive le hérisson! EMBO Rep (2010) 0.75